|
Sepsis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, simvastatin effectively reduced the intestinal levels of tumor necrosis factor α, interleukin-6, high-mobility group box 1, and malondialdehyde and increased the activity of superoxide dismutase in rats with sepsis.
|
30463769 |
2018 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Both HMGB1 and IL-1β have been found to play critical roles in sepsis and post-burn immune dysfunction.
|
29601597 |
2018 |
|
Sepsis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In sepsis and septic shock, pathogen-associated molecular pattern molecules (PAMPS), such as bacterial exotoxins, cause direct cellular damage and/or trigger an immune response in the host often leading to excessive cytokine production, a maladaptive systemic inflammatory response syndrome response (SIRS), and tissue damage that releases DAMPs, such as activated complement and HMGB-1, into the bloodstream causing further organ injury.
|
29370247 |
2018 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The exogenous application of the anti-HMGB1 neutralizing antibody improved efferocytosis, vascular integrity and survival rate in sepsis.
|
30235477 |
2018 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Serum markers associated with the acute proinflammatory phase of sepsis (TNFα, IL-1β, and IL-6) rapidly increased and then progressively decreased during the 30-day period post-CLP, concomitant with a progressive increase in RAGE ligands (S100B, <i>N</i>ϵ-[carboxymethyl]lysine, HSP70, and HMGB1).
|
29127203 |
2018 |
|
Sepsis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Elevated HMGB1 plasma levels were independent from the presence of sepsis.
|
29862569 |
2018 |
|
Sepsis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In this study, we deleted the murine <i>Gstp</i> gene cluster and found that GSTP significantly decreased the mortality of experimental sepsis and reduced related serum level of high mobility group box-1 protein (HMGB1).
|
29520271 |
2018 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings indicate that HMGB1 interacts with LPS to mediate caspase-11-dependent pyroptosis in lethal sepsis.
|
30314759 |
2018 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
High mobility group box 1 (HMGB1) has been proposed as crucial in the pathogenesis of many diseases including sepsis.
|
29988587 |
2018 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
High-mobility group box 1 (HMGB1), a danger-associated molecular pattern protein, is released during infection and contributes to the pathogenesis of sepsis.
|
29563120 |
2018 |
|
Sepsis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Consistent with this, CD11b-deficient mice were more resistant to microbial sepsis with a much lower serum HMGB1 level compared with wild-type mice.
|
29343555 |
2018 |
|
Sepsis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Compared with the healthy controls, patients with sepsis exhibited elevated expression of HMGB1 and decreased expression of miR-25 in serum and PBMCs.
|
30250569 |
2018 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ethyl pyruvate (EP) was previously shown to inhibit HMGB1 release and promote survival during endotoxemia and experimental sepsis.
|
30134814 |
2018 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
HMGB1 is an important sepsis mediator when secreted and also functions as an inducer of autophagy by binding to Beclin 1.
|
29361549 |
2018 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Sirtuin 1 (SIRT1) has been shown to negatively regulate HMGB1 hyperacetylation and its extracellular release in sepsis.
|
29680657 |
2018 |
|
Sepsis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Forced expression of CRBN in macrophage of KO mice suppressed activation of 5' adenosine monophosphate-activated protein kinase (AMPK) and HO-1 and augmented expression of TNF-α and HMGB1 as inhibition of AMPK by compound C. These studies demonstrate the contribution of CRBN expression to the pathogenesis of CLP-induced sepsis and peritoneal macrophage responses and suggest a novel therapeutic modality for polymicrobial sepsis.
|
29170136 |
2018 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
We found that HMGB1 pretreatment improved the survival of sepsis and increased the numbers of BMCs and liver immune cells in CLP mice.
|
29941462 |
2018 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
HuR induces inflammatory responses in HUVECs and murine sepsis via binding to HMGB1.
|
29115544 |
2018 |
|
Sepsis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The inhibition of exosomal microRNA-126 failed to block LPS-induced increase in HMGB1 and VCAM1 protein levels in HMVECs and negated the protective effect of exosomes on sepsis survival.
|
29599080 |
2018 |
|
Sepsis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Therapeutic hypothermia in a rat model of sepsis was associated with lower levels of circulating IL-6 and HMGB1, and less capillary leakage and tissue edema.
|
29505782 |
2018 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
It is interesting that the patterns of change of HMGB1 and SAA over time were distinctive for SIRS and SEPSIS groups.
|
28680349 |
2017 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, we suggested that miR-181a-5p may play a role in regulating DC responses to HMGB1 and serve as evidence indicating that novel therapies targeting miRNAs may be useful for treating immune dysfunction in the setting of sepsis.
|
28947753 |
2017 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
M-BSA ameliorated LPS-induced sepsis and dextran sulfate sodium (DSS)-induced colitis models in which HMGB1 has been shown to play progressive roles.
|
28338748 |
2017 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, our data suggest that HMGB1 accumulation in the late phase of sepsis plays a specific role in the development of postsepsis immunosuppression and specifically affects neutrophil-dependent antibacterial defense mechanisms.
|
27965385 |
2017 |
|
Sepsis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, rTM administered prior to or after LPS suppressed the level of pro-inflammatory cytokine TNF-α in sera at 1-3 h after LPS injection, whereas only the administration of rTM after LPS suppressed the levels of HMGB1 and nucleosome (late-phase mediators of sepsis) (9-12 h) in sera after the LPS injection.
|
28587368 |
2017 |